Skip to Content

Generic Nuvessa Availability

Nuvessa is a brand name of metronidazole topical, approved by the FDA in the following formulation(s):

NUVESSA (metronidazole - gel;vaginal)

  • Manufacturer: ALLERGAN SALES LLC
    Approval date: March 24, 2014
    Strength(s): 1.3% [RLD]

Has a generic version of Nuvessa been approved?

No. There is currently no therapeutically equivalent version of Nuvessa available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nuvessa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
    Patent 7,893,097
    Issued: February 22, 2011
    Inventor(s): Yang; Meidong & Chen; Haigang
    Assignee(s): Dow Pharmaceutical Sciences, Inc.
    The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.
    Patent expiration dates:
    • February 19, 2028
      ✓ 
      Drug product
  • Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
    Patent 8,658,678
    Issued: February 25, 2014
    Assignee(s): Dow Pharmaceutical Sciences, Inc.
    The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.
    Patent expiration dates:
    • June 27, 2028
      ✓ 
      Patent use: TREATMENT OF BACTERIAL VAGINOSIS
  • Compositions for increasing solubility of azole drug compounds that are poorly soluble in water
    Patent 8,877,792
    Issued: November 4, 2014
    Assignee(s): Dow Pharmaceutical Sciences, Inc.
    The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.
    Patent expiration dates:
    • February 2, 2028
      ✓ 
      Drug product
  • High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis
    Patent 8,946,276
    Issued: February 3, 2015
    Assignee(s): Watson Laboratories, Inc.
    The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.
    Patent expiration dates:
    • June 28, 2032
      ✓ 
      Patent use: TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL
  • Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations
    Patent 9,198,858
    Issued: December 1, 2015
    Assignee(s): Watson Pharmaceuticals, Inc.
    The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.
    Patent expiration dates:
    • June 28, 2032
      ✓ 
      Patent use: TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • March 24, 2017 - NEW PRODUCT

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide